Affini-T Therapeutics

Affini-T Therapeutics is a biotechnology company developing novel T cell therapies to treat solid tumors by targeting oncogenic driver mutations. Their therapies leverage two complementary modalities: autologous TCR-T cell therapies and bispecific T cell engagers. They employ cutting-edge platforms for TCR discovery, synthetic biology, and gene editing to create highly specific and potent T cells that can effectively target and destroy cancer cells. Affini-T is driven by their mission to engineer curative T cell therapies that strike at the core of tumor biology and offer the potential to transform patient lives.

Affini-T has assembled a team of leading experts in the fields of immunology, oncology, and cell therapy. Their leadership includes renowned scientists like Jim Allison, Susan Kaech, and Phil Greenberg, as well as experienced executives in the pharmaceutical and biotech industry. Affini-T is well-funded, having raised over $175 million to date from leading investors, including Bayer, Vida Ventures, and Humboldt Fund. They are currently conducting preclinical and clinical trials for their TCR-T cell therapies targeting KRAS and TP53 mutations, with the goal of bringing these transformative therapies to patients in need.

Affini-T Therapeutics offers a mix of on-site and remote work opportunities. The company has a headquarters in Watertown, MA, but some roles are listed as being remote. While the 'Join Us' page doesn't specify the level of flexibility for each role, it does show examples of both on-site and remote positions currently available. Therefore, it appears that the company may be open to accommodating some level of flexibility, but further details would need to be discussed during the hiring process.

Affini-T Therapeutics is a biotechnology company focused on developing transformative cell therapies to cure patients with cancer. Their mission is to engineer curative T cell therapies that target oncogenic driver mutations, striking at the core of tumor biology. Affini-T's co-founders have extensive experience in immune cell therapy innovation, and their team is dedicated to advancing groundbreaking therapies for patients. They leverage high-throughput screening, synthetic biology, and gene editing technologies to develop autologous TCR-T cell therapies and bispecific T Cell Engagers that precisely target oncogenic driver mutations and overcome the limitations of traditional cell therapies.

Affini-T Therapeutics promotes a culture built on collaboration, innovation, and a deep commitment to patient well-being. They emphasize perseverance and drive to deliver, prioritizing patient and people-centricity, and fostering a respectful and inclusive environment where technical excellence and integrity are valued. They encourage agility and adaptability in their pursuit of developing transformative therapies for cancer patients.

Affini-T Therapeutics is committed to fostering a culture of respect and inclusivity, recognizing the importance of diverse perspectives and backgrounds in driving innovation. They strive to create an equitable environment for all employees by promoting equal opportunities for advancement and recognizing the unique contributions of each individual. Their efforts are reflected in their core values, which emphasize respect, inclusivity, and a patient-centric approach, demonstrating a commitment to creating a workplace that embraces and celebrates diversity.